Vaccinex, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 13, 2023 at 07:46 am EST
Share
Vaccinex, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 0.02 million compared to USD 0.05 million a year ago. Net loss was USD 4.91 million compared to USD 4.76 million a year ago. Basic loss per share from continuing operations was USD 15.26 compared to USD 23.38 a year ago.
For the nine months, sales was USD 0.57 million compared to USD 0.05 million a year ago. Net loss was USD 16.93 million compared to USD 14.74 million a year ago. Basic loss per share from continuing operations was USD 59.92 compared to USD 74.76 a year ago.
Vaccinex, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including neurodegenerative diseases, cancer, and autoimmune disorders. Its lead product candidate, pepinemab, is in clinical development for the treatment of Alzheimerâs disease, head and neck, pancreatic and breast cancer. Its lead platform technologies include SEMA4D antibody platform and ActivMAb antibody discovery platform. SEMA4D antibody platform is the application of its knowledge of SEMA4D biology to develop pepinemab for the treatment of various diseases and conditions, including cancer. ActivMAb antibody discovery platform is a human antibody discovery platform based on a method for expressing multipass membrane proteins, as well as large and diverse libraries of high affinity, full-length human monoclonal antibodies on the surface of mammalian pox viruses.